Extended Data Fig. 4: progression-free survival and overall survival in crossover arm. | Nature Cancer

Extended Data Fig. 4: progression-free survival and overall survival in crossover arm.

From: Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLC

Extended Data Fig. 4

N = 45 patients in crossover arm. a, progression-free survival and b, overall survival in patients with metastatic NSCLC without known sensitizing mutations who were treated with 2 L sugemalimab monotherapy in the crossover arm. 2 L, second-line; CI, confidence interval; NSCLC, non-small cell lung cancer.

Source data

Back to article page